Multinational companies operating in India will control nearly 8-10 per cent of the total market with their patented medicine worth $8 billion in the domestic pharmaceutical market by 2015, according to a new survey findings from FICCI-Ernst & Young Report on Compelling Reasons for Doing Clinical Research in India.